Ernexa Therapeutics Warrants (ERNAW)

• Market cap: $1.16M
• 5 days: -22.64%
• 1 month: -20.91%
• 3 months: 188.47%
• 6 months: -14.9%
• Year to date: -14.9%
• 1 year: -14.9%
• 5 years: -14.9%
• 10 years: -14.9%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.

Employees: 5